JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.17 -1.68

Buy Sell

Overview

Share price change

24h

Current

Min

1.16

Max

1.18

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+310.08% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	16M 142M
Previous open	2.85
Previous close	1.17

News Sentiment

By Acuity

34%

66%

71 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 sty 2026, 20:14 UTC

Acquisitions, Mergers, Takeovers

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

31 sty 2026, 18:48 UTC

Acquisitions, Mergers, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31 sty 2026, 16:40 UTC

Earnings

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31 sty 2026, 09:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

31 sty 2026, 07:30 UTC

Earnings

The Exit Rush Is Over for Nontraded BDCs. Cash Keeps Coming Into Private Credit. -- Barrons.com

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 sty 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30 sty 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 sty 2026, 22:20 UTC

Earnings

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 sty 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 sty 2026, 21:42 UTC

Earnings

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 sty 2026, 21:36 UTC

Earnings

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 sty 2026, 21:33 UTC

Earnings

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 sty 2026, 20:42 UTC

Earnings

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 sty 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30 sty 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30 sty 2026, 19:52 UTC

Earnings

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30 sty 2026, 19:29 UTC

Market Talk

Earnings

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30 sty 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

310.08% upside

12 Months Forecast

Average 4.88 USD 310.08%

High 8 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

71 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.